Doer Biologics Enters License Agreement with Lonza to Develop Multispecific Biotherapeutics Using XS® Pichia Expression System

Basel, Switzerland and Hangzhou, China, December 14, 2021 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Biologics") has signed a research and development licensing agreement with Lonza, a global development and production partner for the pharmaceutical, biotech, and nutrition industries, to license the use of Lonza's XS Technologies.^® The platform combines its unique MultipleBody^®And SMART-VHHBody platform technology to develop a new generation of multi-specific antibody drugs. Doer Biologics is a clinical-stage biopharmaceutical innovation company focused on developing multi-domain, multi-specific novel protein drugs in the fields of oncology, endocrinology, metabolic diseases, ophthalmology, and more.

Through this licensing agreement, Doer Biologics can utilize Lonza's XS^® PichiaDevelopment of expression systems that are scalable, stable, and reliable. Doer Biologics can also achieve this through theirPichiaThe system is designed to express and produce multi-specific antibody drugs based on single-domain antibodies (VHH) to meet the unmet clinical needs in the field of tumor immunotherapy. Doer Biologics has previously utilized Lonza XS.^® PichiaThe expression system has achieved initial success in the application of producing multi-domain protein drugs. Therefore, Doer Biologics hopes to continue its cooperation with Lonza and develop more innovative therapeutic biologics.

Head of Lonza's Global Licensing and Formulation ServicesPeter DrocSaid:"The new generation of therapies requires the use of novel expression systems. Lonza has been developing various expression systems to align with industry trends, overcome production bottlenecks, maintain compatibility with downstream processes, and drive clinical breakthroughs. Doer Biologics has an innovative VHH antibody R&D pipeline, and we believe this agreement will further accelerate the advancement of Doer Biologics' candidate antibody drugs from preclinical research to commercial production."

Founder andCEODr. Huang Yanshan commented on the collaboration:"Compared with single-target drugs, multispecific biologics often have stronger potency, longer half-life, and a better therapeutic window, as well as greater clinical development potential. However, designing and developing new multispecific biologics is one of the biggest challenges in achieving new immunotherapies. Lonza's patented expression technology can provide our candidate antibodies with high-efficiency expression and convenient processes, thereby helping us accelerate the development based on Doer Biologics' unique MultipleBody."^®and the production of innovative drugs developed on the SMART-VHHBody platform. We believe that, in Lonza's XS^® Pichia"With the support of the expression system, we can develop high-quality VHH antibody-based multispecific biologics faster and at a lower cost."

For more details about XS Technologies®, please visit: https://pharma.lonza.com/xstechnologies